Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia: Analysis Based on Population-Based Cohort Studies
Uloženo v:
| Název: | Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia: Analysis Based on Population-Based Cohort Studies |
|---|---|
| Autoři: | Saskia Berger, Kristine F. Moseholm, Emilie R. Hegelund, Falko Tesch, Minh Chau S. Nguyen, Laust H. Mortensen, Majken K. Jensen, Jochen Schmitt, Kenneth J. Mukamal |
| Zdroj: | Drugs Aging Berger, S, Moseholm, K F, Hegelund, E R, Tesch, F, Nguyen, M C S, Mortensen, L H, Jensen, M K, Schmitt, J & Mukamal, K J 2024, ' Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia : Analysis Based on Population-Based Cohort Studies ', Drugs and Aging, vol. 41, pp. 423–430 . https://doi.org/10.1007/s40266-024-01112-1 |
| Informace o vydavateli: | Springer Science and Business Media LLC, 2024. |
| Rok vydání: | 2024 |
| Témata: | Male, Aged, 80 and over, Tumor Necrosis Factor-alpha, Incidence, Denmark, Denmark/epidemiology [MeSH], Female [MeSH], Rheumatic Diseases/drug therapy [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Humans [MeSH], Incidence [MeSH], Dementia/chemically induced [MeSH], Cohort Studies [MeSH], Male [MeSH], Original Research Article, Tumor Necrosis Factor-alpha/antagonists, Dementia/epidemiology [MeSH], 3. Good health, Cohort Studies, Rheumatic Diseases, Humans, Dementia, Female, Aged |
| Popis: | Preliminary evidence suggests a possible preventive effect of tumor necrosis factor-α inhibitors (TNFi) on incident dementia. The objective of the analysis was to investigate the association between TNFi and the risk of incident dementia in a population undergoing treatment for rheumatological disorders.We followed patients aged ≥ 65 years with dementia and rheumatological conditions in two cohort studies, DANBIO (N = 21,538), a Danish clinical database, and AOK PLUS (N = 7112), a German health insurance database. We defined incident dementia using diagnostic codes and/or medication use and used Cox regression to compare the associations of TNFi with other rheumatological therapies on the risk of dementia. To ensure that the patients were receiving long-term medication, we included patients with rheumatic diseases and systemic therapies.We observed similar trends towards a lower risk of dementia associated with TNFi versus other anti-inflammatory agents in both cohorts (hazard ratios were 0.92 [95% confidence interval 0.76, 1.10] in DANBIO and 0.89 [95% confidence interval 0.63, 1.24] in AOK PLUS, respectively).Tumor necrosis factor-α inhibitors may decrease the risk of incident dementia although the association did not reach statistical significance in this analysis. Further research, ideally with randomization, is needed to gauge the potential of repurposing TNFi for dementia prevention and/or treatment. |
| Druh dokumentu: | Article Other literature type |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1179-1969 1170-229X |
| DOI: | 10.1007/s40266-024-01112-1 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/38609734 https://curis.ku.dk/ws/files/391934956/s40266_024_01112_1_1_.pdf https://repository.publisso.de/resource/frl:6518104 |
| Rights: | CC BY NC URL: http://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) . |
| Přístupové číslo: | edsair.doi.dedup.....2f7fa0eb8f4edca8f854d818f8b8ce1c |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Preliminary evidence suggests a possible preventive effect of tumor necrosis factor-α inhibitors (TNFi) on incident dementia. The objective of the analysis was to investigate the association between TNFi and the risk of incident dementia in a population undergoing treatment for rheumatological disorders.We followed patients aged ≥ 65 years with dementia and rheumatological conditions in two cohort studies, DANBIO (N = 21,538), a Danish clinical database, and AOK PLUS (N = 7112), a German health insurance database. We defined incident dementia using diagnostic codes and/or medication use and used Cox regression to compare the associations of TNFi with other rheumatological therapies on the risk of dementia. To ensure that the patients were receiving long-term medication, we included patients with rheumatic diseases and systemic therapies.We observed similar trends towards a lower risk of dementia associated with TNFi versus other anti-inflammatory agents in both cohorts (hazard ratios were 0.92 [95% confidence interval 0.76, 1.10] in DANBIO and 0.89 [95% confidence interval 0.63, 1.24] in AOK PLUS, respectively).Tumor necrosis factor-α inhibitors may decrease the risk of incident dementia although the association did not reach statistical significance in this analysis. Further research, ideally with randomization, is needed to gauge the potential of repurposing TNFi for dementia prevention and/or treatment. |
|---|---|
| ISSN: | 11791969 1170229X |
| DOI: | 10.1007/s40266-024-01112-1 |